regulatory
confidence high
sentiment positive
materiality 0.65
Tandem wins FDA 510(k) clearance for tubeless Tandem Mobi insulin pump; US launch planned for H1 2027
TANDEM DIABETES CARE INC
- FDA granted 510(k) clearance on November 12, 2026 for Tandem Mobi as a tubeless automated insulin delivery system.
- New tubeless cartridge and infusion set converts the existing Tandem Mobi pump; infusion set cleared for up to 7 days of wear, cartridge for 3 days of use.
- Mobi keeps Control-IQ+ hybrid closed-loop technology and is now cleared for both tubeless and tubed infusion, which Tandem calls the only pump offering both options.
- Full US commercial launch of the tubeless cartridge and infusion set is planned for the first half of 2027.